DDL, a third-party testing laboratory specialising in medical device and pharmaceutical packaging, combination products, and materials testing, announced on Tuesday that it has launched a new Pharmaceutical Consulting Services programme designed to help pharmaceutical and drug delivery companies navigate complex development challenges, reduce risk and accelerate product development.
The new consulting services provide expert guidance across pharmaceutical primary packaging, containment and delivery systems, and combination products. By integrating technical consulting with DDL's established laboratory testing capabilities, the services aim to help companies develop effective, phase-appropriate testing strategies and address potential challenges before they lead to costly rework or delays.
"Decisions made early in pharmaceutical packaging and drug delivery development can have significant implications for product performance, quality and regulatory success," said Jennifer Riter, vice president of Analytical Testing Services at DDL. "Our goal is to help customers make informed technical decisions, identify potential risks and develop testing strategies that support successful product development from initial concept through commercialisation."
Abbott's Amulet 360 shows high LAA closure rates and low stroke incidence at one year
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Abbott reports 30-day results from clinical trial of SonicForce Coronary IVL System
Edwards Lifesciences wins FDA approval for PASCAL Precision tricuspid repair system
VibroSense Dynamics secures Thai regulatory approval for VibroSense Meter II
SciBase technology selected as primary endpoint in NIH-led skin exposure study
FDA approves Vantis Vascular's 6F CrossFAST model
TWINBIRD launches portable freezer targeting dry-ice-free research cold chains
Urolution Medical secures FDA clearance for OpenFlo urinary catheter
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
Okami Medical receives FDA approval for expanded indication of LOBO Vascular Occluder
Oxurion in talks to acquire Eclevar's MedTech CRO business and assets